Event-Driven Stocks

Merus N.V.

MRUS

Healthcare · Pharmaceutical Preparations · P7 · SEC filings ↗ · Compare ⊕

View price & chart on Yahoo Finance ↗
Signs● 3 good● 4 warningdetails ↓

Financials

SEC XBRL · annual
 FY24FY23FY22FY21FY20FY19
Revenue$36.1M$43.9M$41.6M$49.1M$29.9M$31.1M
Operating income−$272.1M−$156.5M−$160.0M−$90.0M−$75.9M−$58.7M
Net income−$215.3M−$154.9M−$131.2M−$66.8M−$85.5M−$55.2M
Total assets$782.7M$455.5M$376.5M$456.6M$231.2M$263.4M
Total liabilities$134.8M$99.2M$129.5M$140.4M$129.0M$132.1M
Equity$647.9M$356.3M$247.1M$316.2M$102.3M$131.3M
EPS (diluted)$-3.35$-3.00$-2.92$-1.73$-2.92—
Shares out.57.9M46.3M43.5M38.1M29.0M28.9M

Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.

Key ratios

from filings · FY2024
Operating margin
−753.0%
Net margin
−595.9%
Return on equity
−33.2%
Return on assets
−27.5%
Return on capital (ROCE)
−39.1%
Liabilities / assets
17.2%
Debt / equity
0.21×
Book value / share
$11.19
Revenue growth (YoY)
−17.8%
Net income growth (YoY)
—

Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.

Financial health

forensic scores · FY2024
Altman Z″ (distress)
2.72safe
Accruals / assets
−3.8%clean
Piotroski F-Score
4/9mixed

Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.

Quality score

EDS Score
47
/ 100
Profitability 0Growth 0Catalyst 67Earnings quality 67Financial strength 100

Our own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.

Signs

● 4 warning● 3 good
  • Operating losses (negative operating margin)
  • Reported a net loss
  • Revenue declined year-over-year
  • Negative operating cash flow
  • Conservative leverage (liabilities < 50% of assets)
  • Clean earnings (low accruals)
  • Altman Z″ in the safe zone

Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.

5%+ owners

SEC Schedule 13D / 13G · last 3 yrs

Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.

Short interest

FINRA · bi-monthly
SettlementShares shortDays to coverΔ vs prior
Dec 15, 2025817,9361.0-48.0%
Nov 28, 20251.6M1.1+3.0%
Nov 14, 20251.5M1.4-10.5%
Oct 31, 20251.7M1.0-23.0%
Oct 15, 20252.2M1.0-23.7%

Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.

Material events

SEC Form 8-K · most recent

Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.

Recent SEC filings

All filings ↗

Event-driven situations (3)